Engaging Thought Leadership
Over 50 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
Biomarkers Europe 2024
30 September - 01 October 2024 | Basel, Switzerland
Biomarkers Europe 2024
Meet Our Expert Speakers
Biomarkers Europe 2024 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Below are some of our featured speakers:
Amanda Heslegrave
Senior Research Fellow,
University College London
Brian Lockhart
Head of CDx,
Servier
Cornelia Wilson
Reader and Academic Laboratory Director,
Canterbury Christ Church University
Dirk Kemming
Medical Director Diagnostics Europe,
Daiichi Sankyo Europe
Ed Schuuring
Clinical Scientist in Molecular Pathology,
University Medical Center Groningen
Gunther Jansen
Head of Multimodal Data & Analytics,
Novartis
Joanna Janus
Research Programme Manager,
CRUK
Marine Garrido
Global Translational Leader,
Bayer
Olga Nissan
C EO,
Protica Bio
Philip Beer
Chief Scientific Officer,
Step Pharma
Shashank Saran
Associate Director,
AstraZeneca
Aitana Sogorb-Esteve
Senior Research Fellow,
University College London
Alain van Gool
Professor Personalized Healthcare,
Radboud University Medical Center
Aliya Sarmanova
Clinical Development Lead Oncology & Genetics,
Roche
Andrew Janowczyk
Assistant Professor,
Emory University
Bernhard Reis
Expert Biomarker & Translational Medicine Leader; Group Head Biomarker Strategy,
F. Hoffman-La Roche Ltd.
Christian Ruiz
Chief Scientific Officer,
University of Basel
Christophe Le Tourneau
Medical Oncologist,
Institut Curie
Dana Mustafa
Assistant Professor & Group Leader,
Erasmus MC
Daniel Keitley
Research Scientist,
Novo Nordisk
Dylan Powell
Assistant Professor in Public Health & Innovation,
Stirling University
Guillaume Desachy
Head Of Biometrics,
Pierre Fabre
Jacques Colinge
Professor,
University of Montpellier, France
Jan Christoph Brase
Global Translational Science Leader,
Bayer
Jehad Charo
Biomarker & Experimental Medicine Leader,
Hoffmann La Roche Ltd
Jun Frederiksen
Director,
Novo Nordisk
.jpg?length=600&name=3f2cbeb3-fb10-44cb-8cef-b7503b52034b-2-11764368speaker_photo-image1-(4).jpg)
Malleswari Challagundla
Senior Scientist II,
AbbVie Deutschland GmbH & Co. KG
Maximilian Breitner
Lab Head Clinical Bioanalytics,
Sandoz
.png?length=600&name=a328609f-2334-45d5-ba4d-4d8c33a896ea-2-11764368speaker_photo-profile-pic-(1).png)
Mohammad Arastoo
Research Fellow,
University of Aberdeen/ TauRx Pharmaceuticals
Nolwen Guigal-Stephan
Head of Clinical Biomaker Development,
Servier Monde
Sina Nassiri
Principal Bioinformatics Scientists & Team Lead,
Roche
Thomas Jensen
CEO,
Allarity Therapeutics
Vinko Tosevski
Senior Director Translational Research,
Immunos Therapeutics
Meet Our Esteemed Sponsors
Platinum Sponsors
Canopy Biosciences®, a Bruker company
Platinum Sponsor
Canopy Biosciences®, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our flagship CellScape™ Precise Spatial Multiplexing platform is a multiplex immunofluorescence imaging system for the whole-slide analysis of complex tissues and mapping of cell populations with single-cell resolution. Supported by Canopy Spatial Services, we provide a unique collection of spatial and single-cell technologies that accelerate the understanding of cellular diversity and interaction. Learn more at CanopyBiosciences.com.
Gold Sponsors
Labcorp
Gold Sponsor
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.
Personalis
Gold Sponsor
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect MRD and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.
SomaLogic
Gold Sponsor
SomaLogic, a part of Standard BioTools, is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 11,000 protein measurements, covering half the human proteome. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at www.somalogic.com and follow @somalogic on LinkedIn.
Silver Sponsors
.jpg?length=600&name=ff15ed07-b542-4a6e-a9e3-fb741e41930f-2-5668375logo-Abcam_Logo-Lockup_primary-(1).jpg){kind=logo}
Abcam
Silver Sponsor
At abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.
ARC Regulatory
Silver Sponsor
ARC Regulatory is an NI-based specialist regulatory and clinical research organisation, dedicated to supporting companies in the in vitro diagnostic and precision medicine sector. The company’s mission is to be the preferred partner for the global precision medicine and IVD industry, supporting the development of kinder treatments and expediting the highest quality clinical research for improved patient outcomes. In delivering this mission, ARC is proud to have supported more than 50 global biomarker-driven drug programmes with the world’s top targeted therapy R&D leaders.
CellCarta
Silver Sponsor
Leading provider of specialized precision medicine laboratory services with integrated platforms in immunology, histopathology, proteomics, genomics, and related specimen collection and logistics services. CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials, and operates globally with laboratories in Canada, USA, Belgium, Australia, and China.
Discovery Life Sciences
Silver Sponsor
Discovery Life Sciences accelerates the discovery and development of new therapies and diagnostics by providing biopharma and diagnostic companies with the highest quality biospecimens, in vitro preclinical products, and cell & gene therapy starting materials coupled with specialty lab services that are grounded in science and offered at scale to support large scale clinical trials.
Olink
Silver Sponsor
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways. Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base. For more information visit www.olink.com
Precision for Medicine
Silver Sponsor
When Precision for Medicine’s name was chosen back in 2012, it signalled our commitment to a new movement shaping medical R&D, the movement to bring precision to the development of novel treatments. More than just a CRO, under one global roof, we’ve brought precision for medicine by integrating biomarker capabilities, worldwide CRO services, in-country regulatory expertise, specialty and central labs, technical manufacturing solutions and more. Precision is solving the intricate challenges our clients face when developing new therapeutics and together, we are propelling medicine forward.
Rules-Based Medicine (RBM), an IQVIA business
Silver Sponsor
Rules-Based Medicine (RBM), an IQVIA business, is a leading multiplexed immunoassay testing laboratory offering internally developed multi-analyte profiles (MAPs) on the Luminex platform and ultrasensitive Simoa testing. RBM also performs the Olink Target 48 Cytokine panel with additional Olink testing coming soon. RBM provides reproducible and quantitative data for 300+ immunoassays, which provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments from its CLIA-certified biomarker testing laboratory in Austin, TX. RBM also has a novel whole blood immunophenotyping device (TruCulture®). TruCulture enables researchers to reproducibly ascertain information about immune responses to stress or stimulation, including responses to novel therapeutics.
Sapient
Silver Sponsor
Sapient is a biomarker discovery organization providing bespoke services for metabolomics, lipidomics, and proteomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development. Using state-of-the-art, high-throughput mass spectrometry technologies, Sapient enables nontargeted multi-omics measurements to capture thousands of dynamic biomarkers in human, preclinical, and cellular biosamples, across thousands of samples at a time. These technologies are leveraged within a larger discovery infrastructure that includes a comprehensive biocomputational framework for analysis of large-scale, multi-omics data;robust quality control analysis;and mapping of key biomarker-phenotype associations. Sapient can cross-validate discoveries using our proprietary in-house longitudinal Human Biology Database that includes data from over 100,000 human biosamples with paired phenotypic measures. Together our approaches enable rapid identification, validation, and translation of dynamic biomarkers of biological processes, disease mechanisms, and drug response across all drug development phases.
Seer
Silver Sponsor
Seer develops innovative solutions that act as a gateway to the proteome. Our products are designed to accelerate the pace of proteomics by removing the technological barriers that stand between you and the proteomics you want to do. The Proteograph platform enables unbiased, deep, rapid, large-scale proteomics studies – the kind needed to advance our understanding of biology, health, and disease. It is now possible to accurately survey and analyze the full diversity of proteins across individuals, over time. Our goal is to empower the scientific community with tools for exceptional proteomics outcomes.
Sengenics
Silver Sponsor
Sengenics, a functional proteomics company, is committed to advancing precision medicine by empowering researchers with biologically relevant and actionable immunoproteomic insights across a broad spectrum of diseases. At the heart of its mission, Sengenics offers advanced, high-throughput tools using proprietary technology to precisely detect autoantibody biomarkers and protein interactions for basic, translational, and clinical research. Its robust tools have been leveraged by top pharmaceutical companies and leading research institutions to enhance disease understanding and streamline the biomarker pipeline. Sengenics is headquartered in the U.S. and has a worldwide network of offices, distributors, and service providers.
Synexa
Silver Sponsor
Synexa is a global provider of biomarker and large molecule bioanalytical services, providing innovative solutions to support our customers achieve their clinical milestones. Synexa specialises in the development, validation, and delivery of a wide range of complex and custom-designed assays, performed across five laboratory locations in Cape Town, London, Berlin, Turku (Finland) and Rockville (Maryland USA). Our main areas of expertise are; biomarker identification and development, bioanalysis and soluble biomarkers (utilising MSD, ELISA, radioimmunoassay, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical studies. With a focus on science and problem solving we pride ourselves on our ability to tackle complex problems which can be translated into robust and reliable assays to support clinical trial sample analysis.
Ultivue
Silver Sponsor
Ultivue provides researchers with the clearest profile of cancer biology, enabling them to see more, see faster, and see in situ. Through Ultrasensitive InSituPlex® assays and advanced AI-driven STARVUE™ spatial image analysis pipeline, Ultivue empowers scientists developing precision cancer therapies to gain quantitative, high-confidence insights in just a fraction of the time.
Bronze Sponsors
Ardena
Bronze Sponsor
Advancing you to your (pre)clinical milestones quickly, we are carefully engineered to support assay development and validation for your drug. Ardena's bioanalytical platform streamlines regulatory approval. Advanced. Proven. We accelerate your progress through (pre)clinical milestones.
Biognosys
Bronze Sponsor
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery®, TrueTarget®, and TrueSignature® research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.
Cellecta, Inc.
Bronze Sponsor
Cellecta Inc. is a trusted provider of genomic products and services for drug target and biomarker discovery. Since 2006, we have collaborated with the world’s leading pharma, biotech, government, and academic institutions. We apply our extensive expertise in viral vector production, functional screening, custom cell engineering and multiplex qRT-PCR to help researchers find the genes that matter.
Diagnexia Analytix
Bronze Sponsor
Modernize and accelerate your research by expanding your capabilities with Diagnexia’s Research Pathology Services. Implementing Diagnexia’s digital workflow starts with high-quality, AI assisted whole-slide imaging and quality assurance. Your study’s slides are scanned by Diagnexia using our top of the line digital scanners at one of our scanning sites, available throughout the world to meet your needs. Those high-quality images can then be reviewed by Diagnexia’s sub-specialty pathology experts on Diagnexia’s Clinical Research platform, helping to expand your pathology capabilities, reducing pathology bottlenecks and ensuring high quality reads. Our Diagnexia Clinical Research platform is designed to accelerate case reviews, utilize AI tools for precision and build your library of comprehensive digital assets for additional insights for years to come. Partnering with Diagnexia ensures timely and comprehensive pathology analysis, with access to easy to recall whole slide images for current and future studies, saving time, energy and reducing the risk associated with shipping glass slides. Diagnexia’s unique level of expert pathologists can extend your capabilities assisting your team in working the pharmacology and identifying targets and biomarkers to help select the right candidates and targets.. Modernize your research by digitizing, accelerating and informing your clinical trials with Diagnexia.
.jpg?length=600&name=d7563f0d-f009-49cd-8a2d-f682a079a3bb-2-5668375logo-ICON-Positive-logo-JPEG(nostrap).jpg){kind=icon}
ICON
Bronze Sponsor
ICON is the world’s leading clinical research organisation, powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employs approximately 41,150 employees in 113 locations in 53 countries. For further information, visit www.iconplc.com
Surfix Diagnostics
Bronze Sponsor
Surfix is a Dutch diagnostics technology company founded in 2011 and headquartered in Wageningen. Surfix develops POCT solutions with lab precision, utilizing its photonic diagnostics platform that combines six state-of-the-art technologies. The platform is versatile: it can be used for immunoassays as well as for molecular diagnostics. Any protein or nucleic acid-based biomarker in a liquid biopsy can be detected, provided a suitable bioreceptor to capture this biomarker is available. The core of Surfix's diagnostics platform is a photonic biochip, which is integrated into a microfluidic cartridge, both optimized with Surfix's proprietary nanocoatings. The biosensor cartridge is used in combination with a dedicated desktop reader.
Network & Programme Sponsors
Almac Diagnostic Services
Network & Programme Sponsor
Almac Diagnostic Services support global pharma and biotech companies with their biomarker strategies from biomarker discovery through to companion diagnostic partnerships. Almac has clinical and research laboratories in Europe and the USA, alongside strategic partnerships in China, enabling us to support global studies. The services offered fall into three main categories:
• Genomic Services (Range of Platforms & Technologies, Sample Management, Data Sciences) • Clinical Trial Assays (Research Use Assays, Clinical Use Assays, Global Clinical Trial Testing) • Companion Diagnostics (CDx Development, CDx Manufacture, CDx Commercialisation)
https://www.almacgroup.com/diagnostics/
• Genomic Services (Range of Platforms & Technologies, Sample Management, Data Sciences) • Clinical Trial Assays (Research Use Assays, Clinical Use Assays, Global Clinical Trial Testing) • Companion Diagnostics (CDx Development, CDx Manufacture, CDx Commercialisation)
https://www.almacgroup.com/diagnostics/
BioIVT
Network & Programme Sponsor
BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to life science and diagnostic industries. Recognized as an industry leader, we specialize in control and disease state samples including human and animal tissues or preparations, cell and gene therapy products, blood, and other biofluids, as well as ADME contract research services from standalone bioanalytical support through tiered in vitro studies with submission-ready reports to customized consulting. By combining our technical expertise, exceptional customer service, and unmatched access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.
BioLizard
Network & Programme Sponsor
BioLizard is a leading multi-national bioinformatics, data analytics, AI and data management service and consulting company heading digital transformation in the life sciences industry. Headquartered in Ghent, Belgium, BioLizard is the trusted go-to partner for data strategy and execution with companies across the range from drug discovery to clinical research and diagnostics. BioLizard accommodates a uniquely qualified team of 50+ experts, ”The Lizards“, who bring together their expertise and abilities, covering data management, software engineering, bioinformatics, advanced data analytics, and AI. Their joint backgrounds in biology and computer sciences enables them to apply specialist understanding to each client’s data environment, to provide insights and tools that are aligned with the client’s goals and maximize R&D return on investment. Our tools cover literature search - Bio|Refelct, proprietary and public data integration across the full data and omics landscape - Bio|Mx, as well as microbiome specific analytical tools - ProBiome, all integrated in our Bio|Verse framework alongside your data and analytical pipelines.
Concept Life Sciences
Network & Programme Sponsor
Concept Life Sciences, a collaborative client-centred approach. We are a multi-disciplined Contract Research Organisation based in the UK providing market-leading scientific services globally. Over the past 25 years, Concept Life Sciences and its heritage companies have played a pivotal role in guiding numerous clients along their path to clinical success and many of these clients have evolved into enduring scientific collaborators. Within a decade, the collaborative efforts of experts from our heritage businesses — Peakdale Molecular, CXR Biosciences, and Aquila Biomedical — have propelled us beyond the cumulative impact of our individual components, fostering substantial growth and advancement. We are based across 4 research sites in the UK delivering discovery research, as well as GMP, GLP, and GCP-regulated work. Whether it is delivering whole programs of research, or bespoke studies, we deliever a a collaborative client-centred approach. Our services include discovery chemistry, specialist translational biology for immunology, oncology and neuroscience, biologics, biophysical assays services, ADMET & DMPK, bioanalysis, toxicology, histology, analytical services, including materials characterisation and physiochemical analysis, process research and development, and GMP manufacturing.
Firalis Molecular Precision
Network & Programme Sponsor
Firalis Molecular Precision is a One-stop-shop CRO/CDMO equipped with high throughput Multi-Omics technologies dedicated to serve Biotech, Pharma, Academic Research and Health Organizations. Operating in 2 offices (Huningue, France in the heart of the BioValley and Cambridge, USA), Firalis Molecular Precision has a global team of 30+ efficient and reliable experts who have the appropriate knowledge and scientific expertise to understand your critical needs and provide robust trial.
Inside its high qualified envrionment labs, Firalis Molecular Precision offers Multi-omics bioanalytical testing (genomics, transcriptomics, proteomics, lipidomics, metabolomics), biobanking infrastructure, assay development, data analysis and production facilities. Besides, as CDMO, Firalis Molecular Precision boasts a decade-long track record in the Assay-Development and Production sector, dedicated to overseeing the entire spectrum of processes crucial for obtaining CE marking and/or FDA approval for your products.
Firalis’ Group certifications :
- ISO 9001:2015 (certification n° 2014/58992.7) : Quality management system
- ISO 14001:2015 (certification n° 2022/100533.1) : Environnemental management
- ISO 13485:2016 (certification n° 2014/58993.6) : Development and production of immunoassays
- NFS96-900 (certification n° 2016/71433.2) : Biobanking for research (soon be replaced by the ISO 20387)
- ISO 17025 :2017 (accreditation number n°8-3139) : testing activities
Firalis Molecular Precision is since end of August 2023 accredited by the CAP (College of American Pathologists)
Inside its high qualified envrionment labs, Firalis Molecular Precision offers Multi-omics bioanalytical testing (genomics, transcriptomics, proteomics, lipidomics, metabolomics), biobanking infrastructure, assay development, data analysis and production facilities. Besides, as CDMO, Firalis Molecular Precision boasts a decade-long track record in the Assay-Development and Production sector, dedicated to overseeing the entire spectrum of processes crucial for obtaining CE marking and/or FDA approval for your products.
Firalis’ Group certifications :
- ISO 9001:2015 (certification n° 2014/58992.7) : Quality management system
- ISO 14001:2015 (certification n° 2022/100533.1) : Environnemental management
- ISO 13485:2016 (certification n° 2014/58993.6) : Development and production of immunoassays
- NFS96-900 (certification n° 2016/71433.2) : Biobanking for research (soon be replaced by the ISO 20387)
- ISO 17025 :2017 (accreditation number n°8-3139) : testing activities
Firalis Molecular Precision is since end of August 2023 accredited by the CAP (College of American Pathologists)
Hologic Diagenode
Network & Programme Sponsor
Hologic Diagenode is a leading provider in the field of epigenomics, with over 20 years of expertise. Our services can help you advance biomarker discovery and validation by combining the strengths of epigenomics and bioinformatics. This new dimension of epigenomics can offer novel insights that extend beyond genomics, aiding in early detection, patient screening, minimal residual disease (MRD) monitoring, and much more. We partner with you to create a customized, end-to-end service utilizing the best available technology to shorten timelines for translational research and biomarker validation before clinical trials.
Kymos
Network & Programme Sponsor
Kymos is a GLP-certified and GCP-compliant multinational CRO inspected by the EMA and FDA. Our team of experts provides biomarker analysis, supporting you across all phases, from drug discovery to clinical sample analysis reaching multiple therapeutic areas. Equipped with state-of-the-art technologies and techniques such as Meso Scale Discovery (MSD®), Luminex®, qPCR, and LC-MS/MS, we offer a comprehensive catalog of biomarkers. This combination of expertise and technologies allows us to adapt and customize the biomarker determination according to each Clinical or Preclinical study’s specific needs. We are proficient in developing new methods from scratch, and depending on the study scope we can perform fit-to-purpose qualification or validation. Our team is experienced in pharmacodynamic studies to determine drug efficacy and safety (End-point determination), performing biomarker exploratory determinations, and screening of inflammatory markers as inclusion criteria for clinical studies.
Meso Scale Discovery
Network & Programme Sponsor
Meso Scale Discovery (MSD) is a leader in high performance biological detection for preclinical and clinical research. MSD’s proprietary electrochemiluminescence (ECL) platform delivers single- and multiplex assays with exceptional sensitivity, dynamic range, and high-quality data. Our Services group provides expertise in method development for biomarker, PK, ADA and serology assays, including the use of several unique formats. Both bespoke and catalog assays can be run on your own MSD instrument or in our GCLP Bioanalytical Lab.
Mission Bio
Network & Programme Sponsor
Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. The technology discerns key biomarkers to stratify patients more precisely, signal treatment resistance as it begins, and predict relapse for better patient outcomes. Application areas include blood cancers, solid tumors, and genome editing validation. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies around the world to develop treatments and eventually cures for cancer. For example, researchers at Memorial Sloan Kettering Cancer Center (MSK), MD Anderson Cancer Center (MDACC), and the University of California at San Francisco (UCSF) have leveraged the Tapestri Platform to support their research for characterizing clonal dynamics in a variety of cancers, identifying minimal residual disease (MRD), and monitoring treatment response and therapy resistance. The company’s award-winning technology is also leveraged by LabCorp and Agios to enable more efficient clinical trials.
Volition
Network & Programme Sponsor
Volition is a leading epigenetics biomarker company, renowned for its proprietary liquid biopsy immunoassay approach to profiling cell-free circulating nucleosomes. Nu.Q® Discover, a fee for service model, offers access to assays that provide Non-Invasive, Real-Time, Quantitative insights, adding significant value in preclinical and clinical drug development programs across multiple therapeutic areas, including oncology and inflammatory diseases. Nu.Q® Discover, encompasses a range of assays targeting biomarkers associated with innate immune activation (NETosis) and epigenetic inhibitors (HDACi, LSDi, EZH2i, EEDi, SWI/SNF complex and more..). Nu.Q® assays effectively correlate with disease and tumor burden, making them ideal for use as surrogate endpoint markers of treatment response, minimal residual disease, and relapse monitoring. Our development pipeline includes assay development, a novel proteomics approach to epigenetic profiling of circulating nucleosomes using Mass Spec, and Toxicity Monitoring assays.
Start-Ups
Imaging Starts Using Brand New Radiotracer from Nuclidium
The radiotracer is the first part of Nuclidium’s proposed ‘theranostic pipeline’ which aims to diagnose, stage, and then treat prostate cancer.
GHR Foundation Commits $15m to C2N Diagnostics for Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
GHR’s total investment in C2N has now broken $50 million since 2020.
Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality
The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU.
Group Identify Prognostic Biomarker for SCLC and Treatment Using Chemotherapy
SCLC patients that express the gene PCDHB4 have a higher likelihood of developing a resistance to chemotherapy.
Proteomic Analysis of Serum Extracellular Vesicles Reveals Potential Biomarkers for Neuroblastoma
The proteomic analysis of extracellular vesicles is shaping up to be a promising biomarker discovery technique for diseases like neuroblastoma.
Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions
Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.
Congress Center Basel
MCH Swiss Exhibition (Basel) Ltd. Messeplatz 21, CH-4058 Basel
By Rail
Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)
By Tram
From the SBB/SNCF railway station, it’s a ten-minute journey on the No. 1 or 2 Tram to the “Messeplatz/Exhibition Square” stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, “Messeplatz/Exhibition Square” is the second stop on the No. 2 or 6 tram.
By Air
EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport’s No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit: https://www.messe-basel.com/en/about-us/getting-to-messe-basel/
By Car
Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The “Messe” exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.
Our rooms at the Basel Marriott Hotel are now sold out. However, you can still reserve directly with the hotel or explore nearby alternative options by clicking here.
We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.
As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.
Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.
Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.
If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Biomarkers Europe 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.
